Aglaia Oncology Fund

What is Aglaia Oncology Fund?

Aglaia Oncology Funds is focused on investing in early-stage ventures in the oncology drug development sector with an aim to build tomorrow's winners in the fight against cancer. Since its inception in 2004, Aglaia has demonstrated a track record in identifying and nurturing early-stage breakthrough inventions with the potential to transform cancer treatment.

The fund specializes in seed and early-stage investments and operates as a venture capital (VC) entity. The Aglaia team brings decades of experience in cancer research and drug development, and engages closely with innovators and entrepreneurs to define strategic directions for the companies they invest in.

Through collaborative efforts, they bring hands-on experience in designing extensive research and development plans including early screening, animal feasibility studies, and clinical studies. Aglaia Oncology Funds consists of several funds: the dissolved Aglaia Oncology Fund I, the active Aglaia Oncology Fund II, the active Aglaia Oncology Growth Opportunity Fund, the active Aglaia Oncology Growth Opportunity Fund II, and the planned Aglaia Oncology Fund III. These funds have invested in 12 early-stage companies, with 6 companies founded by Aglaia.

Their approach has de-risked and matured these investments to make them attractive for licensing deals, acquisitions, or IPOs. The fund is named after the Greek goddess Aglaia, symbolizing their commitment to contributing to the good health and wellbeing of people by developing innovative cancer therapies.

They have an advisory board with distinguished members from the industry, and their team includes experienced partners and office managers. Aglaia is committed to achieving a positive socio-economic impact alongside compelling financial returns by leveraging the Life Sciences Impact Suite, in partnership with Sinzer — a Grant Thornton company.

This web-based platform measures and reports the socio-economic impact of their investments. Aglaia Management B.V. complies with the sustainable finance disclosure regulation (SFDR), considering sustainability risks in their investment decision process. However, they do not consider adverse impacts of investment decisions on sustainability factors due to the small size of their organization.